Zacks: Analysts Anticipate Esperion Therapeutics Inc (NASDAQ:ESPR) Will Announce Quarterly Sales of $930,000.00

Wall Street brokerages expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce sales of $930,000.00 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Esperion Therapeutics’ earnings, with the lowest sales estimate coming in at $900,000.00 and the highest estimate coming in at $1.00 million. The company is expected to issue its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Esperion Therapeutics will report full-year sales of $147.95 million for the current financial year, with estimates ranging from $146.40 million to $149.00 million. For the next financial year, analysts forecast that the firm will post sales of $175.51 million, with estimates ranging from $115.34 million to $207.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($0.15). The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.05 million. During the same quarter last year, the company posted ($1.71) earnings per share. The business’s revenue for the quarter was up 9720.0% compared to the same quarter last year.

A number of equities analysts recently commented on ESPR shares. Cowen reaffirmed a “buy” rating and set a $80.00 price target on shares of Esperion Therapeutics in a research report on Thursday, July 18th. BidaskClub lowered shares of Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 31st. Goldman Sachs Group raised shares of Esperion Therapeutics from a “sell” rating to a “neutral” rating and lowered their price target for the stock from $55.00 to $45.00 in a research report on Monday, September 16th. Stifel Nicolaus lowered their price target on shares of Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, September 17th. Finally, Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $71.60.

In other news, CEO Timothy M. Mayleben bought 2,500 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were purchased at an average cost of $35.25 per share, with a total value of $88,125.00. Following the acquisition, the chief executive officer now directly owns 76,015 shares in the company, valued at $2,679,528.75. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Target N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was purchased at an average cost of $42.65 per share, for a total transaction of $2,132,500.00. Following the completion of the acquisition, the insider now owns 3,572,964 shares in the company, valued at $152,386,914.60. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 142,500 shares of company stock worth $5,291,825. 7.70% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Aperio Group LLC bought a new position in Esperion Therapeutics in the 2nd quarter valued at about $29,000. Russell Investments Group Ltd. bought a new position in Esperion Therapeutics in the 2nd quarter valued at about $32,000. Royal Bank of Canada increased its holdings in Esperion Therapeutics by 38.1% in the 2nd quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 811 shares during the period. Swiss National Bank increased its holdings in Esperion Therapeutics by 2.0% in the 2nd quarter. Swiss National Bank now owns 44,900 shares of the biopharmaceutical company’s stock valued at $2,089,000 after buying an additional 900 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Esperion Therapeutics by 1.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 104,247 shares of the biopharmaceutical company’s stock valued at $4,850,000 after buying an additional 1,114 shares during the period.

NASDAQ:ESPR traded up $1.41 during mid-day trading on Friday, reaching $38.41. 51,863 shares of the company’s stock were exchanged, compared to its average volume of 360,493. Esperion Therapeutics has a one year low of $33.13 and a one year high of $60.99. The firm has a market capitalization of $994.72 million, a PE ratio of -5.09 and a beta of 1.89. The business’s fifty day simple moving average is $36.62 and its two-hundred day simple moving average is $42.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.65 and a current ratio of 5.65.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: How to build a Fibonacci channel

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.